Aclaris Therapeutics ACRS Royalty — Contract With Customer Liability Current

Similar metrics at other companies

ANFRoyalty — Contract with Customer, Liability, Current

$34.31M+3.8%

NUVBRoyalty Revenue — Deferred Revenue

$300K—

NTRARoyalty — Deferred Revenue

$500K-64.3%

CEVARoyalty — Contract With Customer Asset Net Current

$9.16M+8.3%

OMERRoyalty Obligation Current

$19.86M-5.8%

RARELiabilities For Sales Of Future Royalties Current

$72M+25.5%

Questions, answered.

What is Aclaris Therapeutics's royalty — contract with customer liability current?

Aclaris Therapeutics (ACRS) reported royalty — contract with customer liability current of $4M in Q1 2026.

How has Aclaris Therapeutics's royalty — contract with customer liability current changed year-over-year?

Aclaris Therapeutics's royalty — contract with customer liability current increased by 2.6% year-over-year, from $3.9M to $4M.

What does royalty — contract with customer liability current mean?

This represents the portion of deferred revenue or performance obligations related to royalty agreements that the company expects to satisfy within the next twelve months. It reflects payments received or amounts billed in advance of fulfilling specific contractual obligations tied to royalty-generating assets. Monitoring this balance helps investors understand the short-term revenue recognition pipeline from licensing and royalty arrangements.